Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | NRAS | P01111 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 4/20 | 0.36 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.36 |
| ▸ | ITK | Q08881 | 2/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30698291 | 0.94 | PIK3CD (0.40) | PIK3CDNRASFLT3SCN9AEGFR | |
| SCHEMBL31639286 | 0.88 | KMT2A (0.39) | PIK3CDPIK3CARIPK1SCN9APIM1 | |
| SCHEMBL31639188 | 0.87 | SCN9A (0.39) | PIK3CDPIK3CARIPK1SCN9APIM1 | |
| SCHEMBL30698325 | 0.87 | NRAS (0.37) | PIK3CDNRASFLT3SCN9AEGFR | |
| SCHEMBL31639374 | 0.86 | PIK3CD (0.43) | PIK3CDPIK3CASCN9ANSD2CFTR | |
| SCHEMBL31639111 | 0.85 | NRAS (0.38) | PIK3CDNRASFLT3EGFRNSD2 | |
| SCHEMBL31639332 | 0.83 | EGFR (0.38) | PIK3CDSCN9AEGFRPIM1PIM2 | |
| SCHEMBL30698306 | 0.83 | PIK3CD (0.37) | PIK3CDPIK3CANRASFLT3SCN9A | |
| SCHEMBL27327747 | 0.81 | FLT3 (0.52) | NRASFLT3 | |
| SCHEMBL27330292 | 0.81 | FLT3 (0.52) | NRASFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368648-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4540248-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023245123-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368648-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK1, IRAK2 | PIK3CD 187/4885PIK3CA 112/4885NRAS 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.